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as a readmissions reduction strategy may be ineffective, unless the specific need and 
care content of these additional days is assured.
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Objectives: Medication errors (MEs) frequently contribute for patient’s morbidity 
and mortality in health care settings. The present study was aimed to identify and 
assess the pattern of occurrence of MEs and to develop strategies to prevent these 
MEs. MethOds: It was a prospective study conducted in a teaching hospital over 
a period of 6 months. Trainee clinical pharmacists followed the patients admitted 
to general surgery (GS) wards. MEs occurred and the cause for ME was identified 
by reviewing medical records, interviewing patients and concerned health care 
professionals (HCPs). All identified MEs were documented electronically and were 
evaluated for its nature, extent, cause and outcome. Prevention strategies were 
developed accordingly. Results: A total of 417 MEs were identified in 313 patients 
from 1125 patients followed. Calculated incidence of MEs in GS wards was 27.8%. The 
majority of them were prescribing errors (60.4%), followed by administration errors 
(38.6%) and dispensing errors (9.8%). The common reasons observed for MEs were 
omission error (25%), incorrect drug selection (14%), wrong frequency (10%), poor 
patient adherence to medicines (7%), drug use without indication (7%), improper 
dose (6%), wrong administration (4%) and wrong time (3%). Pantoprazole (27.5%), 
Ceftriaxone (9.8%), Piperacillin-Tazobactum (6.7%), Diclofenac (6.4%) and Tramadol 
(6.2%) were drugs commonly involved in MEs. Majority of MEs (96%) that reached 
to patients were not harmful but 32% of them needed monitoring/intervention to 
ensure patient safety. Around 60% of MEs were due to inappropriate prescribing 
by clinicians followed by patient non-adherence to therapy (14%), improper follow 
up by ward clinical pharmacists (15%) and nursing workload (11%). Strategies were 
designed to prevent commonly identified MEs. cOnclusiOns: MEs can be mini-
mized if patients are monitored correctly on time. Appropriate team work from all 
HCPs can certainly reduce the occurrence of MEs.
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Objectives: An important aim of medical research is often to identify potential 
novel therapeutic targets for disease treatment. Here we investigated whether 
the amount of scientific research (measured as papers published) in a given dis-
ease area correlated with the number of clinical trials, and whether an increased 
amount of research in a disease area resulted in a higher number of FDA approved 
drugs. MethOds: FDA drugs approved between 2000-2013 were identified using the 
online database ‘CenterWatch’, and the number of papers and clinical trials for each 
disease area was established by running comprehensive searches on PubMed from 
1975-2013, and ClinicalTrials.gov from 1999-2013, respectively. The total numbers of 
approved drugs, published papers and clinical trials were compared for each of 17 
disease areas and, to analyse the correlations between these factors, simple regres-
sion analyses were performed. Results: Analysis for correlation between the num-
ber of papers published and the number of clinical trials per disease area revealed 
a strong correlation between these two variables (R square: 0.69, p< 0.001); thus, 
increasing numbers of published papers were associated with increasing numbers 
of clinical trials. Further analyses were carried out to investigate the relationship 
between the number of papers published, or clinical trials, and the number of drugs 
approved by the FDA. Interestingly, these analyses revealed that both clinical trials (R 
square: 0.05, p= 0.41) and published papers (R square: 0.09, p= 0.25) correlated poorly 
with the number of FDA approved drugs per disease area. cOnclusiOns: These 
data suggest that the amount of research significantly correlates with the number 
of clinical trials in a given disease area. However, neither research nor clinical trials 
correlated with the number of drugs approved by the FDA. This may suggest that 
some disease areas could face a bottle neck at the drug approval stage, perhaps 
through difficulties in demonstrating efficacy.
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Objectives: Health policy chances may effect the conducted studies in all 
fields. Pharmacoeconomics dossiers for the reimbursement applications for new 
medicines were not mandatory before year 2008. New molecules need to show cost-
effectiveness and possible budget effect with their applications for reimbursement 
to Social Security Institution from 2008. This policy changing may effect pharmaco-
economics and health outcome studies in Turkey. The aim of the study is to evaluate 
the improvement of pharmacoeconomics and health outcome studies which are 
specific for Turkey in years. MethOds: Database of ISPOR Outcome Research Digest 
were searched online from the begining of database (1998) to 2011 with the key 
words “Turkey” and “Turkish”. The inclusion criteria were taken as study must be 
specific for Turkey and first author must be from Turkey. Included abstract evaluated 
for increasing in years, distribution in study topics and diseases areas. Results: 
121 abstracts were matched with inclusion criteria. First abstracts were published 
in 2000. There were only 16 abstracts in total until 2008. After year 2008, published 
abstracts numbers were increased year by year and reached up to 40 per year in 
2012. 58.7% of all abstracts were Cost Studies(CS). It was followed by Health Care 
Use & Policy Studies(HP) (15.7%) and Patient Reported Outcomes & Preference-Based 
Studies (PRO) (12,7%). 49.3% of all Cost Studies were Cost-Effectiveness studies. 
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Objectives: Effective communication helps us to clearly understand patients or 
situation and enable us to make differences, build trust and respect. If a health 
professional does not have communication skills, it may reduce compliance and 
decrease the quality of health care. The aim of this study was to self-assess the 
communication skills during daily work in delivering care to patients by phar-
macists and physicians at community settings. MethOds: This study is a pilot 
project of an ongoing Research Project aiming to investigate social and behavioral 
insights of pharmaciesy and physicians working in community settings in Serbia, 
started in November 2011. The rating scale is used to test pharmacists’ skills and 
in-patient communication designed for the needs of the research consisted of 31 
claims. Results: The questionnaire completed 157 health professionals (physician, 
pharmacists) from the southeastern and central part of Serbia (75.3 % of which 
were females). The average age of participants were 40.42±9.38 and the average 
years of work experience were 12.92 ± 9.10 years.There is a correlation between the 
age of pharmacists and the following variables: assertiveness (r = 0.456, p < 0.01), 
active listening skills of patient (r = 0.443, p < 0.01), questioning patient (r = 0.455, 
p < 0.01), rhetoric skills (r = 0.540, p< 0.01). ANOVA examined the effects of age on 
empathy (F (4.64) = 1.52, p = 0.01), assertiveness (F (4.64) = 3.54, p = 0.01), rhetoric 
skills (F (4.64) = 2.48, p = 0.01) and adherence to ethical principles (F (4.64) = 1.53, p 
= 0.01). cOnclusiOns: Elder health professionals with greater empathy are more 
assertive having better rhetoric skills and adherence to ethical principles in com-
munication. There is a need to improve the communication skills of young health 
professionals.
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Objectives: To assess the knowledge of health professionals about epidemiological 
and national regulatory issues concerning rare diseases (RD) and access to orphan 
drugs. MethOds: This paper reports some of the results from an ongoing KAP 
study on rare diseases and orphan drugs in the Republic of Serbia (RS). A prospective 
cross-sectional study was conducted from May to June 2013, on a convenient sample 
of licensed pharmacists and physicians from two, large cities’ and its suburbies in 
the central parts of RS. A specially designed KAP instrument in a form of three-part 
questionnaire was applied and these results were related to the assessment of 
concerning knowledge (8 multiple-choice questions) and self-assessment of the 
participants (one question). Results: The study population included 214 health 
workers (151 pharmacists and 63 physicians); the average age of participants was 
40.80±9.45 and the average years of professional practice was 13.14 ± 9.68. Majority 
of the participants (57%) knew the true prevalence of RD and slightly less than third 
of the samples (26.2%) responded correctly to the question of the extent of European 
population suffering from RD. There are major differences in regulatory knowledge 
about access to treatment for rare diseases, as participants answered correctly in 
a wide range of 21% to 67.4%. Most of the health professionals self-estimated that 
possessed little (31.3%) or enough (43.5%) knowledge related to general epidemio-
logical and legislative issues concerning RD and orphan drugs. The average level of 
overall knowledge assessment for all questions and self-assessmentin general was 
3.53 ± 1.58 and 2.04± 0.87 respectively. cOnclusiOns: The majority of respondents 
estimated that possess less knowledge on RD (general information) and drugs to 
treat RD, or insufficiently. The average level of respondents’ knowledge on RD and 
drugs to treat RD was below the average.
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Objectives: The evidence on the influence of timing of discharge on readmission 
risk is inconsistent, showing that both increased length of stay (LOS) and early dis-
charge are associated with an increased risk of readmission. We aimed to test whether 
LOS and day of discharge (i.e., weekend vs. work days) are associated with the risk 
of 30-day emergency readmission. MethOds: Data on first admission to internal 
medicine departments during January – March 2010 was retrieved from Clalit Health 
Services’ data warehouse. Inclusion criteria: LOS of > = 2 nights, age 18+, readmitted 
to an internal medicine demartment or ICU. Predictors: LOS, ACG morbidity categories, 
age, socioeconomic status, and prior health care use. Logistic regression was used to 
model the effect of discharge day and LOS on 30-day emergency readmission, con-
trolling for known risk factors. Results: After adjustment for morbidity, clinical and 
demographic factors, there is an increased risk for 30-day readmissions associated 
with increased length of stay (OR= 1.56 when LOS is 8+ days vs. 2-3 days, p< 0.001). 
Focusing on 2-7 day hospitalizations, the same association is found (OR= 1.47 for LOS 
> 5 days, p< 0.001). Being discharged over the weekend increases the odds of readmis-
sion by 11% (p= 0.04), controlling for all known risk factors. Modeling for an outcome 
of readmission or death, or for a 7-day readmission outcome, resulted in similar find-
ings. cOnclusiOns: Our study showed that contrary to some of the evidence, longer 
hospital stays were associated with increased risk of unplanned readmission. Being 
discharged over the weekend incurs mild additional risk for readmission, especially 
at shorter LOS. These findings suggest that despite short LOS in Israel, increasing LOS 
